Initial Investigation of [18F]P16-129 in Alzheimer's Disease Patients and Healthy Volunteers
Status:
Completed
Trial end date:
2019-11-02
Target enrollment:
Participant gender:
Summary
This study investigates the initial safety profile of [18F]P16-129 in healthy volunteers
including dosimetry determination, and compares the uptake and kinetics of [18F]P16-129 with
the FDA approved drug [18F]florbetapir in the brains of Alzheimer's disease patients.